medigraphic.com
ISSN 0016-3813 (Print)

2008, Number 3

<< Back Next >>

Gac Med Mex 2008; 144 (3)

El costo de las principales enfermedades reumáticas inflamatorias desde la perspectiva del paciente en México

Mould-Quevedo J, Peláez-Ballestas I, Vázquez-Mellado J, Terán-Estrada L, Esquivel-Valerio J, Ventura-Ríos L, Aceves-Ávila FJ, Bernard-Medina AG, Goycochea-Robles MV, Hernández-Garduño A, Burgos-Vargas R, Shumski C, Garza-Elizondo M, Ramos-Remus C, Espinoza-Villalpando J, Álvarez-Hernández E, Flores-Alvarado D, Rodríguez-Amado J, Casasola-Vargas J, Skinner-Taylor C

Language: Spanish
References: 37
Page: 225-231
PDF size: 65.98 Kb.


ABSTRACT

Objective: To estimate the social costs of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and gout from the patient’s perspective.
Methods: We carried out a cross-sectional analysis of the cost and resource utilization of 690 RA, AS, and gout patients from 10 medical centers and private facilities in five cities of Mexico. The information was obtained from the baseline of a dynamic cohort. We estimated out-of-pocket expenses, institutional direct costs, and direct medical costs.
Results: The mean (SD) annual out-of-pocket expense (USD) was $610.0 ($302.2) for RA, $578.6 ($220.5) for AS, and $245.3 ($124.0) for gout. Figures correspond to 15%, 9.6%, and 2.5% of the family income. They also represented 26.1%, 25.3%, and 24.4% of the total annual cost per RA, AS, and gout patients, respectively. The expected direct institutional patient/year costs were 1,724.2 for RA, $1,710.8 for AS, and $760.7 for gout. The total patient annual costs were $2,334.3 for RA, $2,289.4 for AS, and $1,006.1 for gout. Most out-of-pocket expenses were used to purchase drugs, pay for laboratory tests, imaging studies, and alternative therapies.
Conclusions: From the patient’s perspective, the cost of RA, AS, and gout represents 25% of direct medical costs. The cost of RA is higher than that for AS and gout.


REFERENCES

  1. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD Study. Clin Exp Rheumatol 2002;20:617-624.

  2. Burgos-Vargas R, Granados-Arriola J. Ankylosing spondylitis and related diseases in the Mexican mestizo. En: Khan MA, editor. Seronegative spondyloarthropathies. Spine: State of the Art Reviews 4. Philadelphia: Hanley & Belfus; 1990. pp. 665-678.

  3. Ruof J, Hülsemann JL, Stucki L. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol 1999;11:104-109.

  4. Merkesdal S, Ruof J, Mittendorf T, Mau W, Zeidler H. Health economics research in rheumatoid arthritis. Z Rheumatol 2002:61:21-29.

  5. Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 2002;14:121-126.

  6. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28-33.

  7. Alexander CG, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003;290:953-958.

  8. Verstappen SMM, Boonen A, Verkleij H, et al. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005;64:1754-1760.

  9. Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Methods for the economic ealuation of health care programmes. Second edition. Oxford: Oxford University Press; 1999.

  10. Hülsemann JL, Mittendorf T, Merkesdal S, Zeh S, Handelmann S, von der Schulenburg JM, et al. Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis 2005;64:1456-1461.

  11. Boonen A, van der Heijde D, Landewe R, Guillemin F, Spoorenberg A, Schouten H, et al. Costs of ankylosing spondylitis in three European countries: the patient’s perspective. Ann Rheum Dis 2003;62:741-747.

  12. Lapsley HM, March LM, Tribe KL, Cross MJ, Brooks PM. Living with osteoarthritis: patient expenditures, health status, and social impact. Arthritis Care Res 2001;45:301-306.

  13. Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002;61:818-821.

  14. Liang MH, Larson M, Thompson M. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984;27:522-529.

  15. Cooper NJ, Mugford M, Symmons DPM, Barrett EM, Scott DGI. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology 2002;41:767-774.

  16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.

  17. Torres AC, Knaul FM. Determinantes del gasto de bolsillo en salud e implicaciones para el aseguramiento universal en México: 1992-2000. Caleidoscopio de la Salud 2004:209-225.

  18. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368.

  19. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.

  20. Góngora EA. El enfrentamiento a los problemas y el papel del control: Una visión etnopsicológica en un ecosistema con tradición. Tesis doctoral, Facultad de Psicología, UNAM, 2000.

  21. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcón-Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol 1993;11:117-121.

  22. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-2285.

  23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-2291.

  24. Van der Heijde D, Van’t Hof MA, Van Riel P, Van Leeuwen MA, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-181.

  25. Bosh JL, Hunnik MG. Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermitent claudication. Qual Life Resp 2000;9:591-601.

  26. Durán-Arenas L, Gallegos-Carrillo K, Salinas-Escudero G, Martínez-Salgado H. Hacia una base normativa mexicana en la medición de calidad de vida relacionada con la salud, mediante el Formato Corto 36. Salud Publica Mex 2004;46;306-315.

  27. Shiell A, Donaldson C, Mitton C, Currie G. Health economic evaluation. J Epidemiol Community Health 2002;56:85-88.

  28. Villareal-Ríos E, Mathew-Quiroz A, Garza-Elizondo ME, Núñez-Rocha G, Salinas-Martínez AM, Gallegos-Handal M. Costo de la atención de la hipertensión arterial y su impacto en el presupuesto destinado a la salud en México. Salud Publica Mex 2002;44:7-13.

  29. Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center. Clin Exp Rheumatol 1997;15:75-78.

  30. Hernández-Cruz B, Ariza-Ariza R, Cardiel-Rios MH. Cost of standard rheumatology care in active rheumatoid arthritis patients seen in a tertiary care center in Mexico City. Reumatol Clin 2006;2:124-130.

  31. Espinoza-Morales R, Arreola H, Peña A. Peso económico (PE) de la artritis reumatoide (AR) en la población mexicana. Estudio RACE. Reumatol clin 2006;2:15.

  32. Lajas C, Abasolo L, Bellajdel B, Hernández-García C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: A prevalencebased Study. Arthritis Rheum 2003;49:64-70.

  33. Lubeck DP. A Review of the direct costs of rheumatoid arthritis. Managed care versus fee-for-service settings. Pharmacoeconomics 2001;19:811-818.

  34. Lanes SF, Lanza LL, Radensky PW, Yood RA, Mesnan RF, Walker AM, Dreyer NA. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-1481.

  35. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000;27:1156-63.

  36. Wolfe F, Kleinheksel SM, Spitz PQ, Lubeck DP, Fries JF, Young DY, et al. A multicenter study of hospitalization in rheumatoid arthritis: effect of health care system, severity, and regional difference. J Rheumatol 1986;13:277-284.

  37. Meenan RF, Yelin EH, Nevitt M, Epstein WV. The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum 1981;24:544-549.




2020     |     www.medigraphic.com